Six Orthopedic Companies Flying Under the Radar

As part of the annual Top Companies issue of ODT, the editorial team selects six innovators that caught their attention at some point throughout the year. While the primary focus for the issue is on the leading revenue-producing organizations, space is dedicated to these other companies that are making an impact in their own right. Following is a brief synopsis of what makes these six firms noteworthy and offers a glimpse at the affect they are having on the industry. 

Kinomatic & Neurolife

Sam Brusco • Associate Editor

As orthopedic technology continues to evolve, companies are exploring new approaches to improve outcomes beyond the operating room. Here I will highlight two emerging players taking different approaches to patient care: one focused on neuromuscular rehabilitation through advanced recovery technologies, and another combining 3D preoperative modeling, virtual reality surgical simulations, and personalized recovery support for joint replacement patients.

By integrating digital tools, data-driven insights, and patient-specific care models, these companies are helping reshape how procedures are planned, performed, and followed by rehabilitation.

To the OR, and Beyond

Kinomatic was founded in 2021 in Arroyo Grande, Calif., by Shaun Lea. After working for seven years in surgery center development, Lea hoped to fix what he saw as a major flaw in joint replacement surgery—relying on generic surgical plans and the challenging, isolated recovery phase where long-term success is truly decided.

Lea and his company believe that standard orthopedic care treats procedures like an assembly line, using one-size-fits-all alignment instead of accounting for a patient’s biomechanics. Improper orientation of implants can decrease longevity and patient satisfaction, so the company hopes its platform focused on optimizing implant alignment could greatly increase measurable outcomes.

Kinomatic’s platform merges 3D pre-operative modeling, virtual reality surgical simulations, and a concierge recovery model. It converts patient CT scans into 3D joint models that surgeons can use to plan implant size, orientation, and surgical technique. The models are integrated into a VR application for Oculus Quest for preoperative surgical simulation. The platform analyzes over 2 million data points from more than 1,000 unique measurements per patient to choose the best match from more than 30,000 possible implant configurations.

The company secured $4 million of seed financing in June 2026, following a period where it grew revenue sevenfold. The proceeds are being used to scale its artificial intelligence platform and promote opioid-sparing recovery care.

In July, Kinomatic began partnering with human performance company WHOOP to launch the RESTORE pilot. According to the company, RESTORE is the first concierge recovery program for joint replacement that uses continuous biometric monitoring in the post-op experience. The program seeks to close the gap between a successful procedure and consistently positive outcomes.

The WHOOP Unite platform will offer visibility into each patient’s continuous heart rate variability (HRV), sleep, strain, and recovery data. The desired result is higher quality check-ins supported by data, earlier identification of anomalies in recovery, and personalized protocols.

“For decades, progress in orthopedics has been constrained by small, expensive clinical studies that take years to translate into everyday practice. By combining continuous real-world population-level data from WHOOP with Kinomatic’s surgical planning and recovery protocols, we’re setting up a new AI-driven standard in orthopedic care,” said Lea. “Learning from thousands of patients at once to continuously refine the care pathway gives RESTORE the ability to use information that was previously locked away into actionable guidance for both surgeons and patients.”

An Ace up the Sleeve

Columbus, Ohio-based NeuroLife’s journey so far is exceedingly short. The company, which is the market-facing brand of ActivateNeuro, launched in June by closing a $2.9 million seed round with founding partners Battelle and The NeuroTech Institute to answer long-standing needs for paralyzed patients.

The company’s technology is a wearable sleeve that reads electrical signals from muscles and nerves, interprets movement intent, and delivers targeted stimulation to support functional hand and arm recovery during guided therapy. The platform merges high-density neuromuscular sensing, intelligent decoding, and adaptive stimulation to translate neuromuscular signals into real-time feedback and support personalized, signal-driven rehabilitation, analytics, and future  neuro-enabled solutions. One of the main priorities of the wearable sleeve is reducing the debilitating effects of nervous system diseases and dysfunction. The technology can analyze and discreetly track muscle performance improvements and injury risks.

NeuroLife also intends to use its technology for military and combat care. It could be used to assist soldiers with severe limb trauma and traumatic brain injury, and warfighter performance improvement, injury prevention, and rehabilitation. The company also said the sleeve can deliver “hyper-enabled human-machine teaming,” which might speed warfighter performance and aid in nervous system recovery.

The company is currently seeking FDA clearance for its wearable platform and has built a development roadmap focused on clinical validation, regulatory progression, and commercial scalability.

“NeuroLife represents a focused step forward in how rehabilitation can evolve,” said CEO Jon Snyder. “Our goal is to develop a non-invasive platform that supports functional hand and arm use by making therapy more personalized, responsive, and aligned with how the body naturally moves.”

“Battelle has a long history of translating scientific innovation into real-world impact. Our collaboration with NTI and the formation of NeuroLife advances neurotechnology from foundational research into clinical and commercial development,” added Battelle VP of commercial strategy Matt McFarland. “NeuroLife brings the rigor of Battelle’s research capabilities into a platform built for clinical environments and patient impact.”

---

From product launches to M&A and manufacturing trends, the ODT Now delivers the orthopedic device news you need weekly. Subscribe here!

---

Pacira Biosciences & metamorphosis GmbH

Sean Fenske • Editor-in-Chief

Orthopedic innovation around implants has been rapidly advancing for the last decade or more. While the implant remains relatively unchanged (in most cases), the supporting technologies that address virtually all other aspects of the procedure, from pre to during to post, have continued to evolve. While they are still addressing the same clinical concerns—such as pain management, surgical accuracy, clinician fatigue, and other issues—developers are finding novel ways to achieve results more efficiently. 

The following two companies—Pacira BioSciences and metamorphosis GmbH—are addressing different health issues around a total knee replacement. While one seeks to address pain prior to and following the surgery and the other is dedicated to enabling a less cumbersome navigation solution, both are transforming areas around the implant. 

Freezing Out Pain

Pain management was traditionally the realm of pharmaceutical providers. Whether addressing a headache, muscle pain, or more serious concerns, there was likely a pill for it. With greater awareness of the potential issues long-term pharmaceutical use could lead to, patients and innovators sought different solutions. As such, medical devices were developed that would offer a non-drug approach. Such was the case with Pacira BioSciences’ ioveraº device. 

The ioveraº system is FDA-cleared as a drug-free treatment to alleviate pain with intense cold. Through cryoneurolysis, the technology targets a specific nerve with a cold zone that reaches -20°C to disrupt pain transmission. The results from a treatment are felt immediately by the patient and can last up to three months. In some cases, the duration is longer as the nerve regenerates at a rate of 1 to 2 mm per day. 

The device can be used for a range of pain management indications, including before or after knee replacement surgery. The system reduces the need for opioids as soon as 72 hours following a procedure. It can also be used to address osteoarthritis pain in the knee as well as pain in other areas, including the hip, shoulder, chest, foot, ankle, and spine. 

Most recently, Pacira is running a clinical trial for the device on those suffering from upper extremity spasticity, which involves damage or disruption to the upper motor neurons in the brain or spinal cord. It can be caused by stroke, multiple sclerosis, cerebral palsy, brain injury, or spinal cord damage. Pain can be associated with the condition. The trial is expected to be completed in August 2026. 

The ioveraº system was a standout innovation at the 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, and apparently, ODT wasn’t the only one that noticed. About two months ago, it was announced Pacira BioSciences would divest the device in a sale to Zimmer Biomet for up to $140 million. The transaction involves an upfront payment of $70 million with an additional $70 million in potential future revenue-based milestone payments that extend through to the end of 2031. The two companies would also collaborate on finalizing the clinical trial, which could lead to additional payments from Zimmer Biomet. 

Trackerless Robotic Navigation

Robotic-assistance solutions are changing orthopedic surgery. While the jury still seems to be out on just how beneficial these systems are, they are undoubtedly making an impact. It’s likely at some point their advantages will be well established, and they will be the preferred method for orthopedic procedures.

As a result, companies continue to innovate and commercialize new systems with unique capabilities. One such developer sought to address the navigation system involved with the robot. Instead of relying on tracers and physical markers to ensure accuracy of the patient’s anatomy, metamorphosis GmbH integrated artificial intelligence (AI) and standard X-ray imaging to offer a trackerless navigation solution. Additionally, the system operates with unmodified surgical instruments and existing imaging equipment. 

Founded in 2018, the company has been granted more than 35 patents, with over 150 still pending for its technology. It is the brainchild of Professor Schreier (Paderborn University) and co-founder and CTO Dipl.-Ing. Arno Blau. Further, many of the firm’s early employees were from the same University. “Paderborn University offers an environment in which scientific education and practical application are closely interlinked,” explained Schreier. “Many of the skills that we use in the company today were acquired here and developed further over the years.”

Like Pacira, metamorphosis drew attention at the AAOS meeting in 2026, where it presented its collaboration with DePuy Synthes of Johnson & Johnson MedTech—the VELYS Trauma AI-Assisted Surgery system. The technology, powered by metamorphosis, supports femur fracture surgery; femur fractures are one of the most common and clinically relevant injuries in old age. However, the system is branded and distributed by DePuy Synthes. 

The company has also teamed with a number of reputable surgeons who comprise its medical advisory board from hospitals at Stanford, the Colorado University School of Medicine, the University of Washington, and The Johns Hopkins University, among others.

Bone Solutions Inc. & Atreon Orthopedics

Michael Barbella • Managing Editor

Mother Nature really does know best.

She’s unmatched in her environmental handicraft, her life-sustaining capabilities, and her mastery of human biologics.

Yet mortals continue to pursue her level of skill. Unsuccessfully, no less.

These efforts are particularly prominent in orthopedics, where device designers have tried for centuries to replicate the body’s natural musculoskeletal structure. Various materials, ranging from stainless steel, titanium, and cobalt chrome to tantalum, teflon, and polyethylene (vitamin E-infused polyethylene included), have been used to repair or replace damaged, diseased, or worn-out joints or bones with only marginal success. As orthopedic device engineers have learned, the longevity of these materials in the body is limited by the release of metallic ions and wear debris over time. Moreover, wear debris from metal-on-metal or metal-on-polyethylene bearings can lead to osteolysis and ultimately, implant loosening.

Such drawbacks have prompted the development of new biomaterials designed to match the biological and mechanical environment of bone. But these substances have their challenges too—fracture risk (ceramics), hydrophobicity and/or high friction coefficient (Poly ether ether ketone), and durability and manufacturing scalability (nanocomposites).

Faced with yet another obstacle in replicating nature’s design, orthopedic professionals increasingly are adopting biologically-based approaches to repair and regenerate musculoskeletal tissues.

“There’s just a crazy amount of interest in the space. I think more people, as we get better products, will utilize things like synthetics,” Craig McMains, M.D., of OrthoIndy (Indianapolis, Ind.), told Becker’s Spine Review last fall. “The innovation is going to come from personalized medicine. You’re going to have personalized biologics. You’re going to have a biologic that knows how to go into your body and stimulate it to lay down bone in the most effective and the most efficient manner possible. As we expand forward, we’re going to get those solid fusions faster and we’re going to apply that learning of biologics into the implants themselves.”

Nature’s Bone Builder

It’s been hailed as the “mineral of the moment.”

Lauded for its role in promoting better sleep, easing muscle tension, and reducing anxiety, magnesium is an essential mineral that supports hundreds of biochemical reactions in the body. Among those reactions are protein synthesis, muscle and nerve function, blood glucose control, blood pressure regulation, and healthy bone growth.

Relatively standard knowledge to healthcare professionals, the latter biochemical process is the cornerstone of Bone Solutions Inc.’s magnesium-based implant solutions.

The Colleyville, Texas-based company has developed fully resorbable bone substitutes and bone void fillers that leverage magnesium’s natural ability to build bone. Its OSTEO products are synthetic magnesium-potassium composites that initiate a crystallization reaction with phosphate compounds to deliver optimal osteoconductivity. This process promotes osteoblast activity—including cell adhesion, proliferation, and extracellular matrix formation—supporting the critical stages of bone regeneration. 

After less than a minute of mixing, the OSTEO material becomes moldable or injectable, demonstrating cohesive adhesion and radiopacity—making it highly suitable for surgical use.

Mg OSTEOCRETE and Mg OSTEOINJECT earned U.S. Food and Drug Administration clearance last fall for pediatric use. The company claims the authorization highlights the adaptability of its magnesium-based platform in the Sclerograft procedure—a minimally invasive outpatient technique for treating unicameral bone cysts. 

“We are excited to bring our latest orthopedic technological advancement to surgeons and patients,” President/CEO Drew Diaz said in launching Mg OSTEOINJECT. “As the only magnesium-based bone repair product for insufficiency fractures, Mg OSTEOINJECT provides a surgical solution that is unlike anything currently available on the market.”

A Healing Matrix

Consistency is key in rotator cuff repair.

This principle is particularly crucial in biologically based solutions, as even subtle differences in material formulation, polymer chemistry, and performance can impact clinical outcomes.

Such variability is one of the inherent challenges associated with donor-based therapies. Atreon Orthopedics, however, is attempting to eliminate that and many other issues linked to animal-processed collagen or human dermal allografts with its electrospun nanofiber platform technology.

Atreon’s synthetic scaffold approach to tissue repair leverages the patient’s own biology to optimize the microenvironment and mimic natural tissue structure. Its extracellular matrix provides the repair site with a highly porous scaffold for cell attachment, migration, and proliferation. The scaffold wicks and retains autologous blood, cells, and growth factors—with approximately 500% absorption capacity—while its biocompatible synthetic polymers, Polyglycolic acid and Poly(lactide-co-caprolactone), degrade through a biphasic process designed to resorb over a certain amount of time as the tissue remodels natively. 

Atreon Orthopedics’ technology is supported by more than 17 years of tissue engineering research and development, and has been used in more than 20,000 cases since the Ohio-based company launched in 2019. Its ROTIUM Bioresorbable Wick was first authorized for rotator cuff repair in March 2019 and received an expanded use indication from the U.S. Food and Drug Administration (FDA) last March (2025) for the management and protection of any tendon all tendon fixes. In 2025, the American Academy of Orthopaedic Surgeons updated its Clinical Practice Guidelines to include a strong recommendation for biologic augmentation of rotator cuff repair, further validating the need for this type of innovative technology in this space. 

Among other products it its portfolio, the PHOENIX Wound Matrix aims to facilitate wound homeostasis and remodeling through decreasing pH levels, and supporting the formation of health granulation tissue. It is FDA-cleared for all wound types, including surgical wound indications (donor sites/grafts, wound dehiscence, limb salvage), and trauma surgery.

“Successful tissue regeneration hinges on enhancing cellular communication and guiding natural healing,” Dr. Jed Johnson, co-founder/chief technology officer of Nanofiber Solutions, Atreon’s development and manufacturing partner, said upon ROTIUM’s FDA 510(k) clearance last year. “Our Electrospun scaffolds, used in vascular grafts, wound healing, and tissue repair, bring the same innovation to tendon healing—modulating inflammation, promoting revascularization, and reducing scar formation for stronger, more resilient tendon repairs.”

---

Check out last year’s list of six emerging orthopedic companies that caught the ODT editors’ eyes!